Bamboo Joint-Like Appearance of the Stomach: A Stable Endoscopic Landmark for Crohn's Disease Regardless of Anti-Tumor Necrosis Factor alpha Treatment

被引:0
|
作者
Hashiguchi, Keiichi [1 ]
Takeshima, Fuminao [1 ]
Akazawa, Yuko [1 ]
Matsushima, Kayoko [1 ]
Minami, Hitomi [1 ]
Yamaguchi, Naoyuki [1 ]
Shiozawa, Ken [1 ]
Ohnita, Ken [1 ]
Ichikawa, Tatsuki [1 ]
Isomoto, Hajime [1 ]
Nakao, Kazuhiko [1 ]
机构
[1] Nagasaki Univ, Grad Sch Biomed Sci, Dept Gastroenterol & Hepatol, Nagasaki 852, Japan
来源
MEDICAL SCIENCE MONITOR | 2014年 / 20卷
关键词
Crohn's Disease; Diagnosis; Endoscopy; Gastrointestinal; UPPER GASTROINTESTINAL-TRACT; INFLAMMATORY-BOWEL-DISEASE; GASTRIC BODY; INFLIXIMAB; CHILDREN; THERAPY; LESIONS; CARDIA; TRIAL;
D O I
暂无
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background: Bamboo joint-like appearance is a common yet easy-to-miss endoscopic finding in the stomach of patients with Crohn's disease (CD). Bamboo joint-like appearance (BJA) is characterized by swollen longitudinal folds transversed by erosive fissures or linear furrows. However, whether BJA is observed during the remission stage of CD and during the active stage is unclear. In particular, the relationship between the course of BJA and anti-tumor necrosis factor (TNF) alpha therapy has not been studied. We aimed to evaluate the course of BJA in CD patients treated with anti-TNF alpha therapy. Material/Methods: We examined 22 CD patients who underwent esophagogastroduodenal endoscopy before undergoing anti-TNF a treatment. We evaluated the changes in BJA, clinical activity using the CD activity index (CDAI), and endoscopic activity using the simple endoscopic score for CD (SES-CD) from 6 months to 1 year after anti-TNF alpha therapy. Results: Fifteen of 22 patients (68.1%) presented with BJA in the stomach, 13 of whom received follow-up esophagogastroduodenal endoscopy after anti-TNF alpha therapy. The mean CDAI and SES-CD scores significantly improved after anti-TNF alpha therapy (P<0.01). Despite the marked improvements in clinical and endoscopic findings, the BJA of the stomach remained unchanged in all the patients. Conclusions: The findings indicate that BJA is frequently observed in the stomach of CD patients, regardless of whether the patient has active disease or is in remission, even after anti-TNF alpha therapy. Thus, BJA may be a stable endoscopic landmark in CD.
引用
收藏
页码:1918 / 1924
页数:7
相关论文
共 50 条
  • [31] Stricturing and Fistulizing Crohn's Disease Is Associated with Anti-tumor Necrosis Factor-Induced Psoriasis in Patients with Inflammatory Bowel Disease
    Weizman, Adam V.
    Sharma, Robyn
    Afzal, N. M.
    Xu, Wei
    Walsh, Scott
    Stempak, Joanne M.
    Nguyen, Geoffrey C.
    Croitoru, Ken
    Steinhart, A. Hillary
    Silverberg, Mark S.
    DIGESTIVE DISEASES AND SCIENCES, 2018, 63 (09) : 2430 - 2438
  • [32] Paradoxical Arthralgia Secondary to Anti-Tumor-Necrosis-Factor Alpha Therapy in Crohn's Disease
    Thurlapati, Aswani
    Gandu, Siva Santosh Kumar
    Kulkarni, Shreedhar
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (06)
  • [33] Cost-effectiveness and Clinical Outcomes of Early Anti-Tumor Necrosis Factor-α Intervention in Pediatric Crohn's Disease
    Bashir, Naazish S.
    Walters, Thomas D.
    Griffiths, Anne M.
    Ito, Shinya
    Ungar, Wendy J.
    INFLAMMATORY BOWEL DISEASES, 2020, 26 (08) : 1239 - 1250
  • [34] Multiple sclerosis as an adverse effect of anti-tumor necrosis factor agents: an infrequent but important complication of infliximab in Crohn's disease
    Mir Subias, Alberto
    Garcia-Lopez, Santiago
    Sebastian Torres, Berta
    Ollero Domenche, Leticia
    Garcia Gamez, Andres
    Gomollon, Fernando
    GASTROENTEROLOGIA Y HEPATOLOGIA, 2013, 36 (02): : 81 - 85
  • [35] Certolizumab Pegol: A Polyethylene Glycolated Fab' Fragment of Humanized Anti-Tumor Necrosis Factor Alpha Monoclonal Antibody for the Treatment of Crohn's Disease
    Baker, Danial E.
    REVIEWS IN GASTROENTEROLOGICAL DISORDERS, 2008, 8 (04) : 240 - 253
  • [36] Anti-Tumor Necrosis Factor Nonresponders in Crohn's Disease: Therapeutic Strategies
    Louis, E.
    Belaiche, J.
    Reenaers, C.
    DIGESTIVE DISEASES, 2009, 27 (03) : 351 - 357
  • [37] Reduced Imaging Radiation Exposure and Costs Associated with Anti-Tumor Necrosis Factor Therapy in Crohn's Disease
    Patil, Seema A.
    Flasar, Mark H.
    Lin, Jay
    Lingohr-Smith, Melissa
    Skup, Martha
    Wang, Song
    Chao, Jingdong
    Cross, Raymond K.
    DIGESTIVE DISEASES AND SCIENCES, 2019, 64 (01) : 60 - 67
  • [38] Strategies to Optimize Anti-tumor Necrosis Factor Therapy for Perianal Fistulizing Crohn's Disease: A Systematic Review
    Tandon, Parul
    Rhee, Glara Gaeun
    Schwartz, David
    McCurdy, Jeffrey D.
    DIGESTIVE DISEASES AND SCIENCES, 2019, 64 (11) : 3066 - 3077
  • [39] Varicella zoster meningitis complicating combined anti-tumor necrosis factor and corticosteroid therapy in Crohn's disease
    Ma, Christopher
    Walters, Brennan
    Fedorak, Richard N.
    WORLD JOURNAL OF GASTROENTEROLOGY, 2013, 19 (21) : 3347 - 3351
  • [40] Earlier Anti-Tumor Necrosis Factor Therapy of Crohn's Disease Correlates with Slower Progression of Bowel Damage
    Panchal, Hinaben
    Wagner, Mathilde
    Chatterji, Manjil
    Taouli, Bachir
    McBride, Russell
    Patterson, Jeromy R.
    Ungaro, Ryan
    Dubinsky, Marla
    Cho, Judy
    Sachar, David B.
    DIGESTIVE DISEASES AND SCIENCES, 2019, 64 (11) : 3274 - 3283